Copyright © 2013 Chieh-Fang Cheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics, 2010,” CA: A Cancer Journal for Clinicians, vol. 60, pp. 277–300, 2010.
2. J. M. Llovet, S. Ricci, V. Mazzaferro et al., “Sorafenib in advanced hepatocellular carcinoma,” The New England Journal of Medicine, vol. 359, no. 4, pp. 378–390, 2008. View at Publisher · View at Google Scholar · View at Scopus
3. M. Numata, A. Yamamoto, A. Moribayashi, and H. Yamada, “Antitumor components isolated from the Chinese herbal medicine Coix lachryma-jobi,” Planta Medica, vol. 60, no. 4, pp. 356–359, 1994. View at Publisher · View at Google Scholar · View at Scopus
4. M. Su, H. Y. Chung, and Y. Li, “6-O-Angeloylenolin induced cell-cycle arrest and apoptosis in human nasopharyngeal cancer cells,” Chemico-Biological Interactions, vol. 189, pp. 167–176, 2011. View at Publisher · View at Google Scholar
5. H. Ohba, S. Moriwaki, R. Bakalova, S. Yasuda, and N. Yamasaki, “Plant-derived abrin-a induces apoptosis in cultured leukemic cell lines by different mechanisms,” Toxicology and Applied Pharmacology, vol. 195, pp. 182–193, 2004. View at Publisher · View at Google Scholar
6. R. V. Priyadarsini, R. S. Murugan, P. Sripriya, D. Karunagaran, and S. Nagini, “The neem limonoids azadirachtin and nimbolide induce cell cycle arrest and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells,” Free Radical Research, vol. 44, no. 6, pp. 624–634, 2010. View at Publisher · View at Google Scholar · View at Scopus
7. L. Zhao, B. Shan, Y. Du, M. Wang, L. Liu, and F. Z. Ren, “Periplocin from Cortex periplocae inhibits cell growth and down-regulates survivin and c-myc expression in colon cancer in vitro and in vivo via β-catenin/TCF signaling,” Oncology Reports, vol. 24, no. 2, pp. 375–383, 2010. View at Publisher · View at Google Scholar · View at Scopus
8. Z. J. Lu, Y. Zhou, Q. Song et al., “Periplocin inhibits growth of lung cancer in vitro and in vivo by blocking AKT/ERK signaling pathways,” Cellular Physiology and Biochemistry, vol. 26, pp. 609–618, 2010. View at Publisher · View at Google Scholar
9. S. R. Wiley, K. Schooley, P. J. Smolak et al., “Identification and characterization of a new member of the TNF family that induces apoptosis,” Immunity, vol. 3, no. 6, pp. 673–682, 1995. View at Publisher · View at Google Scholar · View at Scopus
10. G. Pan, K. O'Rourke, A. M. Chinnaiyan et al., “The receptor for the cytotoxic ligand TRAIL,” Science, vol. 276, no. 5309, pp. 111–113, 1997. View at Publisher · View at Google Scholar · View at Scopus
11. P. M. Chaudhary, M. Eby, A. Jasmin, A. Bookwalter, J. M. Urray, and L. Hood, “Death receptor 5, a new member of the TNFR family, and DR4 induce FADD- dependent apoptosis and activate the NF-κB pathway,” Immunity, vol. 7, no. 6, pp. 821–830, 1997. View at Publisher · View at Google Scholar · View at Scopus
12. M. J. Smyth, K. Takeda, Y. Hayakawa, J. J. Peschon, M. R. van den Brink, and H. Yagita, “Nature's TRAIL—on a path to cancer immunotherapy,” Immunity, vol. 18, pp. 1–6, 2003. View at Publisher · View at Google Scholar
13. E. Cretney, A. Shanker, H. Yagita, M. J. Smyth, and T. J. Sayers, “TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer,” Immunology & Cell Biology, vol. 84, pp. 87–98, 2006. View at Publisher · View at Google Scholar
14. C. M. M. Van Geelen, E. G. E. De Vries, and S. De Jong, “Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy,” Drug Resistance Updates, vol. 7, no. 6, pp. 345–358, 2004. View at Publisher · View at Google Scholar · View at Scopus
15. Y. Zhang and B. Zhang, “TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5,” Molecular Cancer Research, vol. 6, pp. 1861–1871, 2008. View at Publisher · View at Google Scholar
16. K. Chen, Y. Tu, Y. Zhang, H. C. Blair, L. Zhang, and C. Wu, “PINCH-1 regulates the ERK-Bim pathway and contributes to apoptosis resistance in cancer cells,” The Journal of Biological Chemistry, vol. 283, pp. 2508–2517, 2008.
17. S. Khanbolooki, S. T. Nawrocki, T. Arumugam et al., “Nuclear factor-κB maintains TRAIL resistance in human pancreatic cancer cells,” Molecular Cancer Therapeutics, vol. 5, no. 9, pp. 2251–2260, 2006. View at Publisher · View at Google Scholar · View at Scopus
18. L. Zhang, H. Zhu, J. J. Davis et al., “Lack of p38 MAP kinase activation in TRAIL-resistant cells is not related to the resistance to TRAIL-mediated cell death,” Cancer Biology and Therapy, vol. 3, no. 3, pp. 296–301, 2004. View at Scopus
19. R. R. Rosato, J. A. Almenara, S. Coe, and S. Grant, “The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation,” Cancer Research, vol. 67, no. 19, pp. 9490–9500, 2007. View at Publisher · View at Google Scholar · View at Scopus
20. J. F. Yang, J. G. Cao, L. Tian, and F. Liu, “5, 7-Dimethoxyflavone sensitizes TRAIL-induced apoptosis through DR5 upregulation in hepatocellular carcinoma cells,” Cancer Chemotherapy and Pharmacology, vol. 69, pp. 195–206, 2012. View at Publisher · View at Google Scholar
21. C. H. Ko, S. C. Shen, and Y. C. Chen, “Hydroxylation at C4′ or C6 is essential for apoptosis-inducing activity of flavanone through activation of the caspase-3 cascade and production of reactive oxygen species,” Free Radical Biology and Medicine, vol. 36, no. 7, pp. 897–910, 2004. View at Publisher · View at Google Scholar · View at Scopus
22. O. Pellerito, G. Calvaruso, P. Portanova et al., “The synthetic cannabinoid WIN 55,212-2 sensitizes hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating p8/CCAAT/enhancer binding protein homologous protein (CHOP)/death receptor 5 (DR5) axis,” Molecular Pharmacology, vol. 77, no. 5, pp. 854–863, 2010. View at Publisher · View at Google Scholar · View at Scopus
23. W. Ding, T. Cai, H. Zhu et al., “Synergistic antitumor effect of TRAIL in combination with sunitinib in vitro and in vivo,” Cancer Letters, vol. 293, pp. 158–166, 2010. View at Publisher · View at Google Scholar
24. Y. Hayakawa, V. Screpanti, H. Yagita et al., “NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy,” Journal of Immunology, vol. 172, no. 1, pp. 123–129, 2004. View at Scopus
25. M. J. Smyth, E. Cretney, K. Takeda et al., “Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon γ-dependent natural killer cell protection from tumor metastasis,” Journal of Experimental Medicine, vol. 193, no. 6, pp. 661–670, 2001. View at Publisher · View at Google Scholar · View at Scopus
26. H. Zhang, D. Z. Qian, Y. S. Tan et al., “Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 50, pp. 19579–19586, 2008. View at Publisher · View at Google Scholar · View at Scopus
27. B. Stenkvist, “Is digitalis a therapy for breast carcinoma?” Oncology Reports, vol. 6, pp. 493–496, 1999.
28. B. Stenkvist, E. Pengtsson, B. Dahlqvist, O. Eriksson, T. Jarkrans, and B. Nordin, “Cardiac glycosides and breast cancer, revisited,” The New England Journal of Medicine, vol. 306, no. 8, article 484, 1982.
29. F. Qi, Y. Inagaki, B. Gao et al., “Bufalin and cinobufagin induce apoptosis of human hepatocellular carcinoma cells via Fas- and mitochondria-mediated pathways,” Cancer Science, vol. 102, no. 5, pp. 951–958, 2011. View at Publisher · View at Google Scholar · View at Scopus
30. H. Lin, J. L. Juang, and P. S. Wang, “Involvement of Cdk5/p25 in digoxin-triggered prostate-cancer cell apoptosis,” Journal of Biological Chemistry, vol. 279, no. 28, pp. 29302–29307, 2004. View at Publisher · View at Google Scholar · View at Scopus
31. M. Ramirez-Ortega, G. Zarco, V. Maldonado et al., “Is digitalis compound-induced cardiotoxicity, mediated through guinea-pig cardiomyocytes apoptosis?” European Journal of Pharmacology, vol. 566, no. 1–3, pp. 34–42, 2007. View at Publisher · View at Google Scholar · View at Scopus
32. A. Suliman, A. Lam, R. Datta, and R. K. Srivastava, “Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways,” Oncogene, vol. 20, no. 17, pp. 2122–2133, 2001. View at Publisher · View at Google Scholar · View at Scopus
33. M. A. Degli-Esposti, P. J. Smolak, H. Walczak et al., “Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family,” Journal of Experimental Medicine, vol. 186, no. 7, pp. 1165–1170, 1997. View at Publisher · View at Google Scholar · View at Scopus
34. M. A. Degli-Esposti, W. C. Dougall, P. J. Smolak, J. Y. Waugh, C. A. Smith, and R. G. Goodwin, “The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL- mediated apoptosis, yet retains an incomplete death domain,” Immunity, vol. 7, no. 6, pp. 813–820, 1997. View at Publisher · View at Google Scholar · View at Scopus
35. J. G. Emery, P. McDonnell, M. B. Burke et al., “Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL,” Journal of Biological Chemistry, vol. 273, no. 23, pp. 14363–14367, 1998. View at Publisher · View at Google Scholar · View at Scopus
36. A. Eggert, M. A. Grotzer, T. J. Zuzak et al., “Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced Apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression,” Cancer Research, vol. 61, no. 4, pp. 1314–1319, 2001. View at Scopus
37. P. T. Daniel, T. Wieder, I. Sturm, and K. Schulze-Osthoff, “The kiss of death: promises and failures of death receptors and ligands in cancer therapy,” Leukemia, vol. 15, no. 7, pp. 1022–1032, 2001. View at Publisher · View at Google Scholar · View at Scopus
38. Q. L. Deveraux and J. C. Reed, “IAP family proteins—suppressors of apoptosis,” Genes & Development, vol. 13, pp. 239–252, 1999. View at Publisher · View at Google Scholar
39. I. Tamm, Y. Wang, E. Sausville et al., “IAP-family protein Survivin inhibits caspase activity and apoptosis induced by Fas (CD95), bax, caspases, and anticancer drugs,” Cancer Research, vol. 58, no. 23, pp. 5315–5320, 1998. View at Scopus
40. S. R. Wiley, K. Schooley, P. J. Smolak et al., “Identification and characterization of a new member of the TNF family that induces apoptosis,” Immunity, vol. 3, no. 6, pp. 673–682, 1995. View at Publisher · View at Google Scholar · View at Scopus
41. P. Mirandola, C. Ponti, G. Gobbi et al., “Activated human NK and CD8⁺ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity,” Blood, vol. 104, no. 8, pp. 2418–2424, 2004. View at Publisher · View at Google Scholar · View at Scopus
42. D. Longman and J. A. Callow, “Specific saccharide residues are involved in the recognition of plant root surfaces by zoospores of Pythium aphanidermatum,” Physiological and Molecular Plant Pathology, vol. 30, no. 1, pp. 139–150, 1987. View at Scopus